Abeona Therapeutics Inc. (ABEO)
Stock Price:
$2.95 USD
0.10 (3.51%)
Updated Aug 3, 2020 4:00 PM EDT - Market closed
After-hours: $2.88 -0.07 (-2.37%) Aug 3, 4:45 PM
Key Info
| Market Cap |
246.91M |
| Revenue (ttm) |
482,000 |
| Net Income (ttm) |
-105.89M |
| Shares Out |
83.62M |
| EPS (ttm) |
-1.72 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 3, 2020 |
| Last Price |
$2.95 |
| Previous Close |
$2.85 |
| Change ($) |
0.10 |
| Change (%) |
3.51% |
| Day's Open |
2.86 |
| Day's Range |
2.84 - 2.97 |
| Day's Volume |
504,277 |
| 52-Week Range |
1.35 - 5.19 |
More Stats
| Market Cap |
246.91M |
| Enterprise Value |
138.58M |
| Earnings Date (est) |
Aug 18, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
83.62M |
| Float |
69.60M |
| EPS (basic) |
-1.65 |
| EPS (diluted) |
-1.72 |
| FCF / Share |
-0.72 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3.04M |
| Short Ratio |
2.68 |
| Short % of Float |
4.30% |
| Beta |
1.52 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
512.26 |
| PB Ratio |
1.80 |
| Revenue |
482,000 |
| Operating Income |
-106.25M |
| Net Income |
-105.89M |
| Free Cash Flow |
-66.54M |
| Net Cash |
108.33M |
| Net Cash / Share |
1.29 |
| Gross Margin |
-10,075.93% |
| Operating Margin |
-22,042.95% |
| Profit Margin |
n/a |
| FCF Margin |
-13,804.15% |
| ROA |
-26.87% |
| ROE |
-84.65% |
| ROIC |
-390.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (7)
| Buy |
5 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$9.43*
(219.66% upside)
Low
4.00
Current: $2.95
High
18.00
Target: 9.43
*Average 12-month price target from 7 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | - | 3.00 | 0.84 | 0.89 | 1.04 | 0.93 | 2.04 | 4.40 |
| Revenue Growth | - | 258.18% | -5.85% | -14.52% | 12.43% | -54.7% | -53.63% | - |
| Gross Profit | - | 3.00 | 0.84 | 0.89 | 1.04 | 0.93 | 1.92 | 4.14 |
| Operating Income | -77.09 | -58.17 | -27.84 | -23.88 | -18.55 | -3.13 | -3.80 | -4.32 |
| Net Income | -76.28 | -56.67 | -27.32 | -21.87 | -14.53 | -26.78 | 4.45 | -10.53 |
| Shares Outstanding | 50.35 | 47.53 | 41.64 | 34.18 | 27.60 | 1.94 | 0.50 | 0.48 |
| Earnings Per Share | -1.51 | -1.19 | -0.66 | -0.64 | -0.53 | -15.26 | 3.04 | -25.91 |
| Operating Cash Flow | -62.82 | -39.11 | -22.66 | -13.01 | -10.42 | -1.61 | - | -3.96 |
| Capital Expenditures | -6.31 | -9.24 | -0.86 | -0.52 | -0.31 | - | - | -0.01 |
| Free Cash Flow | -69.13 | -48.35 | -23.52 | -13.53 | -10.73 | -1.61 | - | -3.97 |
| Cash & Equivalents | 129 | 84.97 | 138 | 69.14 | 40.14 | 11.52 | 0.42 | 0.40 |
| Total Debt | 7.95 | - | - | - | - | 0.40 | - | - |
| Net Cash / Debt | 121 | 84.97 | 138 | 69.14 | 40.14 | 11.12 | 0.42 | 0.40 |
| Assets | 223 | 174 | 179 | 111 | 80.06 | 16.58 | 0.61 | 1.73 |
| Liabilities | 44.95 | 40.35 | 8.67 | 11.96 | 12.33 | 11.77 | 15.39 | 18.81 |
| Book Value | 178 | 134 | 170 | 99.10 | 67.72 | 4.82 | -14.78 | -17.08 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Abeona Therapeutics Inc. |
| Country |
United States |
| Employees |
88 |
| CEO |
Joao Siffert |
Stock Information
| Ticker Symbol |
ABEO |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ABEO |
| IPO Date |
September 19, 1980 |
Description
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. Abeona Therapeutics Inc. has a license agreement with REGENXBIO Inc. for the development and commercialization of gene therapies for the treatment of MPS IIIA, MPS IIIB, CLN1 disease, and CLN3 disease. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.